<DOC>
	<DOCNO>NCT02177266</DOCNO>
	<brief_summary>The study determine benefit Colchicine versus placebo cardiac surgery patient post-operative development atrial fibrillation post-pericardiotomy syndrome . Primary Objective . Colchicine reduce composite endpoint incidence post-operative atrial fibrillation post-pericardiotomy syndrome 3 month follow cardiac surgery . Secondary Objectives . 1 . Colchicine reduce incidence constrictive physiology echocardiography 3 month follow cardiac surgery . 2 . Reduction burden symptomatic asymptomatic atrial fibrillation 3 month follow cardiac surgery use colchicine .</brief_summary>
	<brief_title>Colchicine Prevent Post-Pericardiotomy Syndrome Atrial Fibrillation</brief_title>
	<detailed_description>Background . Patients undergoing cardiac surgery risk post-pericardiotomy syndrome post-operative atrial fibrillation . It unknown whether post-pericardiotomy syndrome predisposes patient constrictive pericarditis , cardiac surgery currently common cause constrictive pericarditis . A multicenter European study demonstrate Colchicine promise treatment help prevent development pericardial effusion , atrial fibrillation post-pericardiotomy syndrome ( Imazio et al , Circulation 2011 ; 124:2290-5 ) . However , Colchicine routinely give patient cardiac surgery impact Colchicine post-operative atrial fibrillation constrictive pericarditis study United States . Methods . This randomized , double-blinded placebo control study patient undergo cardiac surgery determine Colchicine comparison placebo effective preventing development post-operative atrial fibrillation , post-pericardiotomy syndrome constrictive physiology . The investigator randomize 278 adult prior undergo cardiac surgery CABG aortic valve disease receive either placebo Colchicine 0.6mg bid one month start 48-72 hour preoperatively . The investigator follow participant 3 month determine development post-pericardiotomy syndrome . In addition , post-operative atrial fibrillation determine base continuous telemetry operation 5 day prior hospital discharge discharge use remote telemetry monitoring BodyGuardianTM . C-reactive protein ( CRP ) obtain prior hospital discharge 3 month follow-up . Echocardiography do initially post-operative course prior hospital discharge 3 month assess presence pericardial effusion , diastolic dysfunction , leave atrial enlargement constrictive physiology . The presence pleural effusion do echocardiogram .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Postpericardiotomy Syndrome</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Inclusion Criteria The study population consist participant enrol Mayo Clinic , Rochester Minnesota . All consecutive adult patient ( age &gt; 40 ) undergo standard ( nonminimally invasive ) coronary artery bypass surgery and/or aortic valve surgery approach enrollment . All patient must able provide inform consent comply 3 month followup . For woman reproductive capability , contraception necessary require . Exclusion Criteria All candidate meet exclusion criterion baseline exclude study participation : eGFR &lt; 30 mL/min/1.73 m2 , serum creatinine &gt; 2.5 mg/dL require dialysis Known permanent current atrial fibrillation ( history paroxysmal atrial fibrillation allow sinus rhythm present ) Allergy colchicine already treat colchicine . Known blood dyscrasia ( acute chronic leukemia , pancytopenia , aplastic anemia , leukopenia ) Known serious gastrointestinal disease Known severe liver disease ( cirrhosis , AST/ALT &gt; 2x upper limit normal , MELD score &gt; 20 ) Women childbearing potential use contraception . Patients HIV AIDS use protease inhibitor result serious colchicine toxicity . Patients treat strong CYP3A4 inhibitor ( clarithromycin/erythyromycin , chloramphenicol , ketoconazole/itraconazole , nefazodone ) . There risk rhabdomyolysis use digoxin colchicine , exclude patient require ongoing treatment digoxin . Inability unwillingness individual give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>